Back to top

Image: Bigstock

GL Stock Gains 22.3% in a Year: Here's What Investors Should Know

Read MoreHide Full Article

Key Takeaways

  • Globe Life expects 6-8% premium growth in 2027, supported by higher life and health insurance revenues.
  • Rising investment income, AI adoption and distribution expansion are expected to support GL's growth.
  • Globe Life targets 2027 operating EPS of $16.10-$17.10 despite agent declines and weaker DTC life sales.

Shares of Globe Life Inc. (GL - Free Report) have rallied 22.3% over the past year, outperforming the industry’s growth of 12.6%.

The performance reflects its consistent operating performance, healthy premium growth, higher investment income and disciplined capital allocation. Strong share repurchases and improving earnings expectations have further supported the stock.

Shares of other insurers, such as Unum Group (UNM - Free Report) and AMERISAFE, Inc. (AMSF - Free Report) , have gained 13.7% and 5.2%, respectively, while Aflac Incorporated (AFL - Free Report) has declined 52.8% over the past year.

1-Year Price Performance: GL, AFL, AMSF, UNM & Industry

Zacks Investment Research

Image Source: Zacks Investment Research

GL Shares Are Affordable

Globe Life shares are trading at a discount compared to the industry. Its forward price-to-earnings multiple of 9.88 is lower than the industry average of 13.56. It has a Value Score of B.

Zacks Investment Research

Image Source: Zacks Investment Research

Shares of other insurers, such as Unum Group and AMERISAFE, are also trading at a discount to the industry average, while Aflac is trading at a higher multiple.

GL’s Optimistic Growth Projection

The Zacks Consensus Estimate for Globe Life’s 2026 earnings per share indicates a year-over-year increase of 6.6%. The consensus estimate for revenues is pegged at $6.40 billion, implying a 6.1% year-over-year improvement.

The consensus estimate for 2027 earnings per share and revenues calls for a jump of 5.8% and 5.8%, respectively, from the corresponding 2026 estimates.

GL’s Target Price Reflects Potential Upside

Based on short-term price targets offered by 13 analysts, the Zacks average price target is $186.15 per share. The average indicates a potential 15.8% upside from the last closing price.

Zacks Investment Research

Image Source: Zacks Investment Research

GL’s Return on Equity

GL’s trailing 12-month return on equity is 19.5%, ahead of the industry average of 13%, reflecting how effectively the company is utilizing its shareholders’ equity.

Key Points to Note for Globe Life

Globe Life continues to strengthen its growth outlook through a combination of premium expansion, technology adoption, distribution investments, rising investment income and shareholder-friendly capital deployment. Its diversified life and supplemental health insurance portfolio, supported by multiple distribution channels, provides opportunities for sustained premium and earnings growth.

Globe Life's premium growth remains a key earnings driver. In the third quarter of 2026, total premium revenues increased 7% year over year, while health premium revenues grew 16% to $447 million. Growth was supported by Medicare Supplement rate increases and strong sales at United American and Family Heritage. Management expects 2027 total premium revenue growth of 6-8%, with life premiums projected to increase 4% and health premiums 13-15%.

Higher investment income is expected to support earnings growth. In the third quarter, net investment income increased 3% year over year to $296 million. Reinvestment at higher yields is expected to support investment income growth as existing securities mature. Management expects excess investment income to increase 10-11% in 2026, supported by higher investment yields and growth in invested assets.

Technology investments could further enhance profitability. Globe Life is expanding artificial intelligence across applications, customer service and claims processing. Broader AI adoption is expected to improve underwriting, sales productivity and customer engagement while gradually lowering administrative costs.

Distribution expansion is another important growth lever. Liberty National's average producing agent count increased 9% year over year, while Family Heritage's agent count rose 1%. Management expects mid- to high-single-digit life sales growth at American Income in 2027. Liberty National and Family Heritage are also expected to deliver growth in sales, supporting future premium generation.

Globe Life continues to generate substantial cash flow, supporting dividends and share repurchases. The company repurchased approximately 1.1 million shares for $185 million in the third quarter and expects full-year 2026 share repurchases of $725-$775 million. Globe Life expects 2027 net operating EPS of $16.10-$17.10, indicating approximately 7% growth at the midpoint. Continued premium growth and pricing actions are expected to support earnings expansion.

Risks for GL

Globe Life's middle-income customer base makes sales and retention vulnerable to inflation and economic uncertainty. Weak consumer confidence could increase lapses and slow sales.

American Income's producing agents declined 7% year over year to 11,331 in the third quarter of 2026, while DTC net life sales fell 12%. Recruiting challenges and weaker digital conversions could constrain growth despite management's targeted sales recovery in 2027.

Litigation, Medicare claims delays and Evry losses have weakened health margins, while regulatory and claims volatility could further pressure earnings.

Conclusion

Globe Life’s growth prospects remain supported by steady premium expansion, particularly in supplemental health, alongside investments in technology and distribution. Rising AI adoption could improve operating efficiency and support underwriting and sales productivity, while favorable investment yields continue to bolster earnings. However, subdued consumer demand, distribution challenges and health underwriting volatility remain key risks.

Higher return on equity, affordability of shares and solid growth projections should continue to benefit the insurer over the long term. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in